Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

EXPAND Clinical Investigators

Research output: Contribution to journalArticlepeer-review

387 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study'. Together they form a unique fingerprint.

Medicine & Life Sciences